Abstract
Controversies exist regarding the immunoregulatory properties of K+ ATP channel modulators. We investigated the effects of aprikalim, a K+ ATP-dependent channels activator, and glibenclamide and gliclazide, two inhibitors of K+ ATP-dependent channels, on the prolongation of heart allograft survival in the rat. Nine groups (n ≥ 5) were involved in this study with the Brown-Norway to Lewis rat combination treated with aprikalim, glibenclamide, gliclazide, and/or cyclosporine. The results indicate that modulators of K+ ATP-dependent channels can improve the survival of rat heart allograft without interfering with the immunosuppressive properties of cyclosporine. © 1999 Wiley-Liss, Inc. MICROSURGERY 19:314–317 1999
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
